Navigation Links
New Revolutionary Drug Could Stop the Spread of HIV

A new revolutionary drug manufactured by a US biotechnology company could block the spread of HIV, say scientists after finding its benefits in a small-scale human trial. //

Human Immunodeficiency Virus (HIV) steadily weakens the body's immune system until it can no longer fight off infections such as pneumonia, diarrhea, tumours and other illnesses.

Unable to fight back, most people die within three years of the first signs of the disease. Most of all HIV infections have been transmitted through unprotected sexual intercourse with someone who is already infected with the disease.

Panacos Pharmaceuticals in Gaithersburg, Maryland, which is developing PA-457, hopes now to begin trials this month to test how well the drug works in patients whose existing drug regimes are failing, reported the science portal EurekAlert.

About 80 percent of people being treated for HIV show resistance to one or more of their drugs, a spokesman for Panacos said. There are several existing ways of tackling HIV.

Many medications work by blocking reverse transcriptase, an enzyme that enables HIV to replicate within a cell. Others disable protease, which helps to assemble the virus into particles to infect other cells.

The new drug, a derivative of betulinic acid, is a cheap by-product of the paper industry and one of a new class of drugs called maturation inhibitors.

It works by interfering with the production of the capsid protein, a conical "shield" which protects the genetic material of HIV inside it.

The drug is still in its early stages, and will not be generally available for at least three years, he said.

The small human trial of the drug reported that, given on its own, it rapidly clears most HIV from the blood, the study published in the Journal of Virology claimed.

Worldwide, over 36 million people were infected at the end of 2000 with HIV, the most dangerous sexually transmitted infection, with 95 percent of them in developing countries.

(Source: IANS)
'"/>




Related medicine news :

1. Revolutionary Simple Pregnancy Blood Test Can Save Both Mother And Child
2. Revolutionary Pill Cuts Risk of Breast Cancer
3. A Revolutionary New Treatment For Cancer Available In Australia
4. Revolutionary New Treatment Plan Developed For Treatment Of Unexplained Symptoms
5. Revolutionary Net To Control Malaria
6. Revolutionary Net To Control Malaria
7. Revolutionary Eye Cancer Treatment
8. Revolutionary Pill Promises Relief for Hay Fever Sufferers
9. Lean Protein Could Be Key to Obesity Drugs
10. Nasal Spray Could Take Drugs Direct to Brain.
11. Nasal Spray Could Take Drugs Directly to Brain
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/26/2016)... ... 26, 2016 , ... Dr. James Maisel will present on ... Chapter on June 4, 2016, 1:30-3:30 pm at the Farmingdale Public Library. The ... Group of New York , is a Board Certified ophthalmologist who completed his ...
(Date:5/26/2016)... ... May 26, 2016 , ... Leadership of Life Science Logistics ... organization has earned its ISO 13485 certification, indicating the company’s quality control system ... and policies associated with ISO quality standard 13485. , BSI Group America, ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... multitude of activities from daily practices, arts & crafts, discussions, and games all ... East-D’Anna and Christy Evans have combined backgrounds in kids’ yoga, collegiate sport yoga ...
(Date:5/26/2016)... ... 26, 2016 , ... Power Systems, a leading developer and ... Certification Course in Stoughton, Massachusetts. The course was led by Power Systems’ Education ... hour interactive course to qualify participants as certified PowerWave trainers. , PowerWave ...
(Date:5/26/2016)... ... ... A health conscious snack that doesn't sacrifice taste? It's possible! In one ... buzz in the protein product community by offering an alternative to the traditional bar ... with 11 grams of protein and made from a healthy blend of high quality ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... FDA 510(k) clearance covers Confocal Miniprobes ... and surgical applications Mauna Kea Technologies ... multidisciplinary confocal laser endomicroscopy (CLE) platform, today announced ... the 12 th 510(k) clearance from United ... FDA clearance covers Confocal Miniprobes indicated for use ...
(Date:5/25/2016)... , Germany and ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime ... a licensing and co-development agreement with Therawis Diagnostics GmbH to ... will be to develop and market PITX2 as a marker ... other high-risk breast cancer patients. "We are pleased ...
(Date:5/25/2016)... NEW YORK , May 25, 2016 ... Device Market Size, Share, Development, Growth and Demand Forecast ... Insulin Syringe, Insulin Pump and Others)" published by P&S ... valued at $9,998.3 million in 2015, and it is ... 2016-2022. Based on type, the insulin pump segment is ...
Breaking Medicine Technology: